Skip to main content

Table 7 Univariable and multivariable survival analysis for PFS using Cox proportional hazards models

From: Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

Group

Immune Biomarker

Univariable

Multivariable

HR (95% CI)

p-value

HR (95% CI)

p-value

Cohort A

ALCs

> = 800

< 800

5.08 (1.62, 15.92)

0.005

4.25 (1.21, 14.87)

0.024

CD4 plus CD8 counts

> = 500

< 500

6.36 (1.76, 22.97)

0.005

8.89 (1.89, 41.86)

0.006

PD-L1 IHC

> = 50%

< 50%

1.17 (0.42, 3.30)

0.764

TMB

> = 10

< 10

0.99 (0.13, 7.66)

0.989

Cohort B

ALCs

> = 800

< 800

2.63 (1.16, 5.99)

0.021

2.50 (1.05, 5.95)

0.038

CD4 plus CD8 counts

> = 500

< 500

2.70 (1.21, 6.04)

0.016

2.94 (1.18, 7.37)

0.021

PD-L1 IHC

> = 50%

< 50%

2.36 (1.04, 5.37)

0.040

5.21 (1.77, 15.38)

0.003

TMB

> = 10

< 10

3.16 (1.27, 7.86)

0.013

4.11 (1.58, 10.70)

0.004